The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis.
Philippe Langella, Research Director at the French National Institute of Agricultural Research, discussed the potential of Faecalibacterium Prausnitzii as Live Biotherapeutics for several disease.
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x.
The findings of a recent study may help to develop diagnostic or therapeutic approaches to reduce bacterial bloodstream infections in newborns.
Cocaine users have an altered gut and oral microbiota composition and function, which can be rescued by rTMS-induced cocaine abstinence.
MAP 315, is a novel live biotherapeutic product being developed for the treatment of ulcerative colitis and was discovered and developed using Microba’s data-driven Therapeutics Platform.
Together with Professor Lorenzo Morelli we focused on the significant role of diet and the microbiome in terms of health benefits, food production, and agri-industry systems.
By providing insights into how the gut microbiota influences cancer susceptibility, the findings may help to develop new therapies or dietary interventions.
The findings of a recent study suggest that vaginal bacteria can spread to the urinary tract of men and reshape the male urethral microbiota.
Biofarma Group's R&D to support people in the pre-depressive phase.
